I say that the tofacitinib AdComm opinion to be positive by plurality as well. The immune safety issues can be in the label like the oncology risks for Humira et al. Will be interesting the view on the radiology results. Surely there was an FDA dialogue on this as well as with the efficacy endpoints.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.